People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

The UK is poised to lead the next great leap in agriculture, with gene-editing technology offering a lifeline to a ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The X contains more genes related to brain function than does any other chromosome. “The X chromosome may be a treasure trove of genes that influence cognition, and these could be therapeutic targets, ...

The articles in this special issue highlight the diversity and complexity of research into reproductive health, including the need for a better understanding of the fundamental biology of reproduction ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

The emergent field of CRISPR/Cas sensing technology is showing promise as a new paradigm in clinical diagnostics, although widespread clinical adoption remains limited. This perspective paper ...